Results 11 to 20 of about 250,617 (262)
Cells, 2022 The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism.
Christopher Forcados +4 more
doaj +4 more sources
Pharmacologic Control of CAR T Cells [PDF]
International Journal of Molecular Sciences, 2021 Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors.
Benjamin Caulier +2 more
openaire +4 more sources
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire +2 more sources
Biomarker Research, 2017 Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood.
Cheng Zhang +3 more
openaire +3 more sources
Oncogenesis, 2021 Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao +14 more
doaj +1 more source
Journal of Hematology & Oncology, 2019 The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL.
Juanjuan Zhao, Yongping Song, Delong Liu
doaj +1 more source
Journal of Hematology & Oncology, 2019 Background Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability
Hejin Jia +12 more
doaj +1 more source
Donor T cells for CAR T cell therapy
Biomarker Research, 2022 Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed.
Tiffany C. Y. Tang +5 more
doaj +1 more source
Molecular Therapy: Nucleic AcidsSeveral allogeneic chimeric antigen receptor (CAR) T-cell therapies in clinical trials rely on CRISPR-Cas genome editing, but the enzyme’s random repair mechanism increases the risk of undesired off-target effects, challenging safe CAR T-cell generation.
Tanya Hundal +8 more
doaj +1 more source